Vutrisiran
Vutrisiran is the medicine in Amvuttra, a solution for injection under the skin. The US label calls it a transthyretin-directed small interfering RNA, and says it causes degradation of the messenger RNA for transthyretin (TTR) through RNA interference, which reduces TTR protein and its deposits in tissues. The label lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The atlas holds no trial results for it.
Also called Amvuttra · Vutrisiran sodium
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2604578 (vutrisiran); the label names the salt vutrisiran sodium, whose UNII 28O0WP6Z1P is a broad match to the ingredient. RxClass lists the FDA established pharmacologic classes Small Interfering RNA and Transthyretin-directed RNA Interaction, so the record is filed under the class page on the second. MeSH has no descriptor for vutrisiran (an exact-label lookup returned an empty list on 2026-11-19). The label read is the Alnylam Pharmaceuticals, Inc. label for Amvuttra, application NDA215515, effective 2025-11-06 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indications, the class and the mechanism sentence only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Classification codes
-
28O0WP6Z1PVutrisiran sodium
Claims and evidence
Context Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra
- Recipient
- Recipient not specified
- Population
- Adults in the two groups the indications section of the label names: adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. The passages read give no other age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN)
- Adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)
- Excluded
- None stated
The US label of Amvuttra (vutrisiran injection; Alnylam Pharmaceuticals, Inc., application NDA215515; the version dated 2025-11-06 in openFDA) calls the product a transthyretin-directed small interfering RNA. It lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
Applies to Recipient not specified Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The polyneuropathy indication concerns the nerves, not the heart, and the atlas gives it no page of its own. The label read has no boxed warning section. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA215515.
- Retrieved
- Source effective date
- 2025-11-06
- Source state
- Current
- Version fingerprint
4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251106.
- Retrieved
- Source effective date
- 2025-11-06
- Source state
- Current
- Version fingerprint
4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], highlights sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-VUT-LB-04).
- Retrieved
- Source effective date
- 2025-11-06
- Source state
- Current
- Version fingerprint
4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], section 1.2
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-VUT-LB-05).
- Retrieved
- Source effective date
- 2025-11-06
- Source state
- Current
- Version fingerprint
4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], section 1.1
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-VUT-LB-06).
- Retrieved
- Source effective date
- 2025-11-06
- Source state
- Current
- Version fingerprint
4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits, as an indication: Cardiac amyloidosis
Applies to Recipient not specified Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra
The US label of Amvuttra (vutrisiran injection; Alnylam Pharmaceuticals, Inc., application NDA215515; the version dated 2025-11-06 in openFDA) calls the product a transthyretin-directed small interfering RNA. It lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The polyneuropathy indication concerns the nerves, not the heart, and the atlas gives it no page of its own. The label read has no boxed warning section. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:vutrisiran- Content hash
ac42f7425d7305845a0d90f50c84e34d55a513a3b095867d83d88057d404bc23